Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Chunlei Li

Yanhui Li

Caixia Wang

Lan Zhang

Dongmin Shen

Li Zhang

Yongfeng Li

Min Liang

Yajuan Wang

Shixia Wang

Xian Xiu

Xiaodong Wang

Yanling Du

Wenmin Guo

Shasha Yang

Xuekun Yao

Hongmei Luo

Jing Yuan

Jianfei Xue

Zhibin Meng

Yumei Wang

Kun Lou

Yueying Peng

Jinxu Wang

Dongjian Chen

Shan Chen

Meng Zhou

Xiaoli Wang

Lingling Wang

Disclosed is a use of a liposomal pharmaceutical preparation of mitoxantrone in the preparation of a medicament for treating lymphoma, wherein the lymphoma is preferably non-Hodgkin's lymphoma, further preferably aggressive non-Hodgkin's lymphoma, more preferably diffuse large B-cell lymphoma or peripheral T-cell lymphoma, and more further preferably relapsed or refractory diffuse large B-cell lymphoma or peripheral T-cell lymphoma. The mitoxantrone liposomes are used as single anti-tumor therapeutic agent without being combined with other anti-tumor agents.

Use of mitoxantrone liposome for treating non-Hodgkin's lymphoma

A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase may contain sulfobutyl ether cyclodextrin and an active compound.

Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt

Purified therapeutic nanoparticles are provided herein. Such nanoparticles comprise an active pharmaceutical ingredient and human serum albumin, wherein the weight ratio of human serum albumin to the active ingredient in the therapeutic nanoparticles is from 0.01:1 to 1:1, and wherein the nanoparticles are substantially free of free human serum albumin that is not incorporated in the nanoparticles. The present disclosure also provides pharmaceutical compositions that comprise the purified therapeutic nanoparticles and are also substantially free of free human serum albumin. Methods for preparing and using the purified therapeutic nanoparticles and compositions thereof are also provided.

Purified therapeutic nanoparticles and preparation methods thereof

The present invention relates to a liposomal pharmaceutical preparation containing a multivalent ionic drug, a process for the preparation of the liposomal pharmaceutical preparation, and a use thereof in the treatment of diseases, in which the liposome has a size of about 30-80 nm, and the phospholipid bilayer has a phospholipid with a Tm higher than body temperature, so that the phase transition temperature of the liposome is higher than the body temperature.

Liposomal pharmaceutical preparation and method for manufacturing the same

A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase contains sulfobutyl ether cyclodextrin and active compound. Said sulfobutyl ether cyclodextrin is sulfobutyl ether &#x3b1;-cyclodextrin, sulfobutyl ether &#x3b2;-cyclodextrin, or sulfobutyl ether &#x3b3;-cyclodextrin.

Growing community of inventors

Hebei, China

Chunlei Li